DDInter548 DDInter1082
A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed) The FDA withdrew its approval for the use of all oral and parenteral drug products containing 25 milligrams or more of diethylstilbestrol per unit dose.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Diethylstilbestrol {u} (Compound) resembles {v} (Compound) Ritodrine
Diethylstilbestrol {u} (Compound) resembles {v} (Compound) Dienestrol
Diethylstilbestrol {u} (Compound) binds {v} (Gene) CYP2C8
Diethylstilbestrol {u} (Compound) upregulates {v} (Gene) CCP110
Diethylstilbestrol {u} (Compound) downregulates {v} (Gene) RPS4Y1
Diethylstilbestrol (Compound) resembles Ritodrine (Compound)
Diethylstilbestrol (Compound) resembles Dienestrol (Compound)
Diethylstilbestrol (Compound) binds CYP2C8 (Gene)
Diethylstilbestrol (Compound) upregulates CCP110 (Gene)
Diethylstilbestrol (Compound) downregulates RPS4Y1 (Gene)